An interdisciplinary research team has demonstrated a durable and lasting response to a novel treatment—combined locoregional therapy and immunotherapy (LRT-IO)—for advanced liver cancer patients. The ...
Liver cancer is one of the fastest-rising causes of cancer-related deaths in the UK and the third-leading cause of cancer ...
Professor Albert Chan Chi-yan (left) and Dr Chiang Chi-leung collaborate once more to develop the innovative ‘cocktail’ strategy—Locoregional therapy and immunotherapy (LRT-IO) approach. This method ...
Stockholm - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces that the results from the phase 1b/ ...
A new Cedars-Sinai Cancer study shows that patients with advanced liver cancer who receive immunotherapy to shrink their tumors have improved outcomes after liver transplant or tumor removal.
Higher baseline and early-treatment physical/role functioning (EORTC QLQ-C30) predicted longer atezolizumab–bevacizumab duration and improved survival, supporting routine PRO integration into advanced ...
The FDA approved a phase 3 trial for amezalpat with Tecentriq and Avastin in hepatocellular carcinoma treatment. Amezalpat targets tumor cells and modulates the tumor microenvironment, potentially ...
(Boston)—The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is replaced by scar tissue. The scar tissue blocks the flow of blood ...
MASLD and Liver Cancer: What’s the Link? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where too much fat builds up in your liver. Unlike fatty liver caused by heavy ...
As fatty liver disease emerges as a growing health concern, Firstpost brings out experts’ view on how rising obesity, ...
Cancer of the liver, seen in a radial cross-section abdominal scan. (Photo by: BSIP/Universal Images Group via Getty Images) The number of new liver cancer cases will nearly double in the next 25 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results